Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of injection site experience of semaglutide 0.25 mg SC administered by two products
2019-002284-10Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Intensity of injection site pain. Started Jun 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2019-002284-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002284-10.